Australia is carefully awaiting the arrival of retatrutide, a groundbreaking dual GIP and GLP-1 receptor agonist that's generating significant buzz in the global weight management landscape. Developed by Novo Nordisk, https://joycesevo444655.governor-wiki.com/2562464/this_new_drug_retatrutide_australia_a_promising_hope_for_obesity_treatment